Blau Farmacêutica S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023
Share
Blau Farmacêutica S.A. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was BRL 364.31 million compared to BRL 365.24 million a year ago. Net income was BRL 70.79 million compared to BRL 112.4 million a year ago. Basic earnings per share from continuing operations was BRL 0.4 compared to BRL 0.63 a year ago. Diluted earnings per share from continuing operations was BRL 0.4 compared to BRL 0.63 a year ago.
For the six months, sales was BRL 622.51 million compared to BRL 678.58 million a year ago. Net income was BRL 122.74 million compared to BRL 173.86 million a year ago. Basic earnings per share from continuing operations was BRL 0.69 compared to BRL 0.97 a year ago. Diluted earnings per share from continuing operations was BRL 0.69 compared to BRL 0.97 a year ago.
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.